UNSPSC 51281521: Pretomanid

Pretomanid is an antibiotic medication used for the treatment of multi-drug-resistant tuberculosis affecting the lungs. It is generally used together with bedaquiline and linezolid. It is taken by mouth.

UNSPSC 51281521 Pretomanid, a Commodity code, does not align with the recent state and local solicitations tagged under it. The three most recent opportunities—a Seminole County IFB for naloxone and drug deactivation systems, a Texas HHS RFI on direct-to-manufacturer prescription programs, and a Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products—address naloxone procurement, pharmacy benefit management infrastructure, and broad-spectrum pharmaceutical supply contracting. None targets pretomanid specifically, a tuberculosis treatment drug with niche clinical use. State and local health departments and cooperative purchasing entities do source pharmaceuticals through these channels, but the code's nominal focus does not reflect the actual procurement activity recorded under it.

The issuing bodies reflect state health agencies and county public health infrastructure: Seminole County, Florida (county health procurement); Texas Health and Human Services Commission (state health authority conducting market research); and Minnesota Department of Administration on behalf of a multistate cooperative. Geographic activity appears concentrated in Florida and Texas, with multistate cooperative participation extending to Oregon. The Seminole County IFB, posted June 30, 2026 with response due July 26, 2023, seeks naloxone and safe drug deactivation systems with quarterly deliveries and a two-year initial term plus one-year renewal option. The Minnesota MMCAP RFP, posted January 20, 2026 with proposals due March 26, 2026, establishes contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with contract effectiveness July 1, 2026. The code shows no focused recent activity in pretomanid procurement and appears misapplied to these broader pharmaceutical and public health initiatives.